Lixte Ptb Ratio from 2010 to 2024

LIXTW Stock  USD 0.03  0.0001  0.36%   
Lixte Biotechnology PTB Ratio yearly trend continues to be fairly stable with very little volatility. PTB Ratio is likely to outpace its year average in 2024. PTB Ratio is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on Lixte Biotechnology's equity relative to its net asset value. View All Fundamentals
 
PTB Ratio  
First Reported
2010-12-31
Previous Quarter
1.12477289
Current Value
1.18
Quarterly Volatility
67.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Ptb Ratio Growth Pattern

Below is the plot of the Ptb Ratio of Lixte Biotechnology Holdings over the last few years. It is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value. Lixte Biotechnology's PTB Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Ptb Ratio10 Years Trend
Slightly volatile
   Ptb Ratio   
       Timeline  

Lixte Ptb Ratio Regression Statistics

Arithmetic Mean(14,680)
Coefficient Of Variation(461.88)
Mean Deviation32,354
Median3.12
Standard Deviation67,805
Sample Variance4.6B
Range294.4K
R-Value0.37
Mean Square Error4.3B
R-Squared0.14
Significance0.17
Slope5,639
Total Sum of Squares64.4B

Lixte Ptb Ratio History

2024 1.18
2023 1.12
2022 0.16
2021 3.35
2020 7.13
2019 3.12
2018 2.21

About Lixte Biotechnology Financial Statements

Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Ptb Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
PTB Ratio 1.12  1.18 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.